Early identification of false positives in high-throughput screening for activators of p53-DNA interaction

Journal of Biomolecular Screening

Volumn 11, Issue 4, 2006, Pages 341-350

  Wölcke, Julian ^a   Hunt, Nicholas ^b   Jungmann, Joern ^a   Ullmann, Dirk ^a  

^a EVOTEC AG   (Germany)

^b genteQ GmbH   (Germany)

Author keywords

Autofluorescent compounds; Confocal spectroscopy; False positives; Fluorescence polarization; High throughput screening; p53 activators; p53 protein purification

Indexed keywords

MUTANT PROTEIN; PROTEIN ANTIBODY; PROTEIN P53;

ACCURACY; ADDITION REACTION; ANALYTIC METHOD; ANIMAL CELL; ANISOTROPY; ARTICLE; ARTIFACT; BINDING AFFINITY; CANCER THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DNA BINDING; EVALUATION; FALSE POSITIVE RESULT; FLUORESCENCE CORRELATION SPECTROSCOPY; HIGH THROUGHPUT SCREENING; INTERMETHOD COMPARISON; LATENT PERIOD; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DNA INTERACTION; STATISTICAL ANALYSIS; VALIDITY; WILD TYPE;

ALGORITHMS; ANIMALS; BASE SEQUENCE; CELL LINE; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; FALSE POSITIVE REACTIONS; FLUORESCENCE POLARIZATION; GENES, P53; HUMANS; KINETICS; MUTATION; RECOMBINANT PROTEINS; SPECTROMETRY, FLUORESCENCE; SPODOPTERA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33744932217     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057106286652     Document Type: Article

References (30)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70.
2. Vogelstein LL: Surfing the p53 network. Nature 2000;408:307-310.
3. Hupp TR, Meek DW, Midgley CA, Lane DP: Regulation of the specific DNA binding function of p53. Cell 1992;71:875-886.
4. Lane DP, Hupp TR: Drug Discovery and p53. Drug Discov Today 2003;8:347-355.
5. Bullock AN, Fersht AR: Rescuing the function of mutant p53. Nat Rev Cancer 2001;1:68-75.
6. Kim AL, Raffo AJ, Brandt-Rauf PW, Pincus MR, Monaco R, Abarzua P, et al: Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J Biol Chem 1999;274:34924-34931.
7. Hupp TR, Sparks A, Lane DP: Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995;83,237-245.
8. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, et al: Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Med 1997;3:632-638.
9. Issaeva N, Friedler A, Bozko P, Wiman KG, Fersht AR, Selivanova G: Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci 2003;100:13303-13307.
10. Caron de Fromentel C. Gruel N, Venot C, Debussche L, Conseiller E, Dureuil C, et al: Restoration of transcriptional activity of p53 mutants in human tumor cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene 1999;18:551-557.
11. Foster BA, Coffey HA, Morin MJ, Rastinejad F: Pharmacological rescue of mutant p53 conformation and function. Science 1999;286:2507-2510.
12. Selivanova G, Kawasaki T, Ryabchenko L, Wiman KG: Reactivation of mutant p53: a new strategy for cancer therapy. Semin Cancer Biol 1998;8:369-378.
13. DeDecker BS: Allosteric drugs: thinking outside the active-site box. Chem Biol 2000;7:R103-R107.
14. Komarova EA, Chernov MV, Franks R, Wang K, Armin G, Zelnick CR, et al: Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 1997;16:1391-1400.
15. Westphal CH, Hoyes KP, Canman CE, Huang X, Kastan MB, Hendry JH, et al: Loss of atm radiosensitizes multiple p53 null tissues. Cancer Res 1998;58:5637-5739.
16. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chemov MV, et al: A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999;285:1733-1737.
17. Palo K, Brand L, Eggeling C, Jager S, Kask P, Gall K: Fluorescence intensity and lifetime distribution analysis: toward higher accuracy in fluorescence fluctuation spectroscopy. Biophys J 2002;83:605-618.
18. Eggeling C, Brand L, Ullmann D, Jager S: Highly sensitive fluorescence detection technology currently available for HTS. Drug Discov Today 2003;8:632-641.
19. Haupts U, Rudiger M, Ashman S, Turconi S, Bingham R, Wharton C, et al: Single-molecule detection technologies in miniaturized high-throughput screening: fluorescence intensity distribution analysis. J Biomol Screen 2003;8:19-33.
20. Wright PA, Boyd HF, Bethell RC, Busch M, Gribbon P, Kraemer J, et al: Development of a 1-1μ scale assay for mitogen-activated kinase kinase 7 using 2-D fluorescence intensity distribution analysis anisotropy. J Biomol Screen 2002;7:419-428.
21. Wölcke J, Reimann M, Klumpp M, Gohler T, Kim E, Deppert W: Analysis of p53 "latency" and "activation" by fluorescence correlation spectroscopy: evidence for different modes of high affinity DNA binding. J Biol Chem 2003;278:32587-32595.
22. Kask P, Ullmann D, Gall K: Fluorescence intensity distribution analysis. Proc Natl Acad Sci 1999;96:13756-13761.
23. Magde D, Elson EL, Webb WW: Thermodynamic fluctuations in a reacting system - measurement by fluorescence correlation spectroscopy. Phys Rev Lett 1972;29:704-708.
24. Kask P, Palo K, Fay N, Brand L, Mets Ü, Ullmann D, et al: Two-dimensional fluorescence intensity distribution analysis: theory and applications. Biophys J 2000;78:1703-1713.
25. Kim E, Albrechtsen N, Deppert W: DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53. Oncogene 1997;15:857-869. Erratum in Oncogene 1997;15:2385.
26. Mundt M, Hupp T, Fritsche M, Merkle C, Hansen S, Lane D, et al: Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential. Oncogene 1997;15:237-244.
27. Zhang J-H, Chung TDY, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
28. Ullmann D, Busch M, Mander TH: Fluorescence correlation spectroscopy-based screening technology. Inn Pharm Tech 1999;99:30-40.
29. Jäger S, Garbow N, Kirsch A, Preckel H, Gandenberger FU, Herrenknecht K, et al: A modular, fully integrated ultra-high-throughput screening system based on confocal fluorescence analysis techniques. J Biomol Screen 2003;8:648-659.
30. Lane D, Hupp TR: Drug discovery and p53. Drug Discov Today 2003;8:347-355.